about Us
about Us
Shengtai Biotech (Guangzhou) Medical Technology Co., Ltd. (hereinafter referred to as "Shengtai Biotech") was established in Guangzhou Development Zone in December 2021. The company's paid-in registered capital is 10 million yuan. Capital holdings. The company was founded by a team of returned doctors from the United States who have worked in the field of medical devices (especially IVD) for many years, focusing on the research and development, production and sales of in vitro diagnostic reagents and instruments.At present, Shengtai Biotechnology has established a research and development center in Xiamen and a holding subsidiary in Houston, USA.
With the concept of "faster, more accurate and more accessible diagnostic product development", the company focuses on the development of series products based on "photo-induced chemiluminescence homogeneous POCT", series products based on "microfluidic chip molecular POCT" and products based on "nano Particle home self-examination” series of products cover major diseases (myocardial infarction, heart failure), chronic disease management, prenatal and postnatal care, and rapid and accurate diagnosis of infectious pathogens. At present, nearly 100 products of Shengtai Biotech have passed the EU CE certification, the US FDA certification, and the ISO13485 quality system certification of internationally renowned institutions, which guarantees the quality of the company's research and development products.
With the concept of "faster, more accurate and more accessible diagnostic product development", the company focuses on the development of series products based on "photo-induced chemiluminescence homogeneous POCT", series products based on "microfluidic chip molecular POCT" and products based on "nano Particle home self-examination” series of products cover major diseases (myocardial infarction, heart failure), chronic disease management, prenatal and postnatal care, and rapid and accurate diagnosis of infectious pathogens. At present, nearly 100 products of Shengtai Biotech have passed the EU CE certification, the US FDA certification, and the ISO13485 quality system certification of internationally renowned institutions, which guarantees the quality of the company's research and development products.
Since 2020, COVID-19 has swept the world and brought great challenges to all mankind. In the fight against the epidemic, Shengtai Biotech has independently developed 6 new coronavirus antigen rapid detection kits, all of which have obtained EU CE certification, and one of them is an antigen triple detection reagent for influenza A/B/new coronavirus The box can quickly and accurately identify the infection of influenza A or B or new crown within 15 minutes. The above-mentioned related products have been successfully exported to Hong Kong, Vietnam, Thailand, Malaysia and other regions and countries, and the performance of the products has been widely recognized by the international community.
